National Cancer Center, Korea
Clinical trials sponsored by National Cancer Center, Korea, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo aims to stop breast cancer return after failed chemo Results expected Dec 2026 (estimated)
- New drug combo targets tough adrenal cancer Results expected Feb 2027 (estimated)
- New hope for rare pancreatic cancer: experimental drug enters trial Results expected Mar 2027 (estimated)
- Exercise may ease Chemo's nerve pain, new study hopes to prove Results expected Jul 2027 (estimated)
-
New hope for advanced liver cancer: drug trial targets patients with limited options
Disease control Not yet recruitingThis phase 2 trial tests the drug lenvatinib as a first treatment for 50 adults with advanced liver cancer (HCC) who cannot have surgery or other curative treatments. The goal is to see if lenvatinib can control the cancer and improve survival. Participants must have measurable t…
Phase 2 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Exercise may ease Chemo's nerve pain, new study hopes to prove
Symptom relief Not yet recruitingThis study looks at whether exercise can lessen nerve damage caused by certain chemotherapy drugs. About 140 people with colorectal or gynecologic cancer will either exercise or receive usual care. Researchers will measure nerve function, blood markers, and quality of life to see…
Sponsor: National Cancer Center, Korea • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC